Reza Indrakusuma

Reza Indrakusuma

Auto-generated profile, based on publicly available information

Reza Indrakusuma

Amsterdam UMC, Department of Surgery, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MAMitzi van Andel
Mitzi van Andel
RIReza Indrakusuma
Reza Indrakusuma
HJHamid Jalalzadeh
Hamid Jalalzadeh
RBRon Balm
Ron Balm
JTJanneke Timmermans
Janneke Timmermans
MGMaarten Groenink
Maarten Groenink
The COMPARE trial showed a small but significant beneficial effect of 3-year losartan treatment on aortic root dilatation rate in adults with Marfan syndrome (MFS). However, no significant effect was found on clinical endpoints, possibly due to a short follow-up period. The aim of the current study was therefore to investigate the long-term clinical outcomes after losartan treatment. In the original COMPARE study (inclusion 2008–2009), adult patients with MFS (n = 233) were randomly allocated to either the angiotensin-II receptor blocker losartan® on top of regular treatment (β-blockers in 71% of the patients) or no additional medication. After the COMPARE trial period of 3 years, study subjects chose to continue their losartan medication or not. In a median follow-up period of 8 years, 75 patients continued losartan medication, whereas 78 patients, originally allocated to the control group, never used losartan after inclusion. No differences existed between baseline characteristics of the two groups except for age at inclusion [losartan 34 (interquartile range, IQR 26–43) years, control 41 (IQR 30–52) years; P = 0.031], and β-blocker use (losartan 81%, control 64%; P = 0.022). A pathological FBN1 mutation was present in 76% of patients and 58% of the patients were male. Clinical endpoints, defined as all-cause mortality, aortic dissection/rupture, elective aortic root replacement, reoperation, and vascular graft implantation beyond the aortic root, were compared between the two groups. A per-patient composite endpoint was also analysed. Five deaths, 14 aortic dissections, 23 aortic root replacements, 3 reoperations, and 3 vascular graft implantations beyond the aortic root occurred during follow-up. Except for aortic root replacement, all endpoints occurred in patients with an operated aortic root. Patients who used losartan during the entire follow-up period showed a reduced number of events compared to the control group (death: 0 vs. 5, P = 0.014; aortic dissection: 3 vs. 11, P = 0.013; elective aortic root replacement: 10 vs. 13, P = 0.264; reoperation: 1 vs. 2, P = 0.463; vascular graft implantations beyond the aortic root 0 vs. 3, P = 0.071; and composite endpoint: 14 vs. 26, P = 0.019). These results remained similar when corrected for age and β-blocker use in a multivariate analysis. These results suggest a clinical benefit of combined losartan and β-blocker treatment in patients with MFS.

1 July 2018 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
RIReza Indrakusuma
Reza Indrakusuma
HJHamid Jalalzadeh
Hamid Jalalzadeh
JMJessica E. van der Meij
Jessica E. van der Meij
RBRon Balm
Ron Balm
MKMark J.W. Koelemay
Mark J.W. Koelemay

1 January 2018 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
RIReza Indrakusuma
Reza Indrakusuma
JZJendé L. Zijlmans
Jendé L. Zijlmans
HJHamid Jalalzadeh
Hamid Jalalzadeh
RPR. Nils Planken
R. Nils Planken
RBRon Balm
Ron Balm
MKMark J.W. Koelemay
Mark J.W. Koelemay

6 April 2018 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
MSM. J. Sweeting
M. J. Sweeting
PUP. Ulug
P. Ulug
JRJ. Roy
J. Roy
RHRebecka Hultgren
Rebecka Hultgren
RIR. Indrakusuma
R. Indrakusuma
SISTAR Cohort investigators
STAR Cohort investigators
Background The aim of this study was to develop a 48‐h mortality risk score, which included morphology data, for patients with ruptured abdominal aortic aneurysm presenting to an emergency department, and to assess its predictive accuracy and clinical effectiveness in triaging patients to immediate aneurysm repair, transfer or palliative care. Methods Data from patients in the IMPROVE (Immediate Management of the Patient With Ruptured Aneurysm: Open Versus Endovascular Repair) randomized trial were used to develop the risk score. Variables considered included age, sex, haemodynamic markers and aortic morphology. Backwards selection was used to identify relevant predictors. Predictive performance was assessed using calibration plots and the C‐statistic. Validation of the newly developed and other previously published scores was conducted in four external populations. The net benefit of treating patients based on a risk threshold compared with treating none was quantified. Results Data from 536 patients in the IMPROVE trial were included. The final variables retained were age, sex, haemoglobin level, serum creatinine level, systolic BP, aortic neck length and angle, and acute myocardial ischaemia. The discrimination of the score for 48‐h mortality in the IMPROVE data was reasonable (C‐statistic 0·710, 95 per cent c.i. 0·659 to 0·760), but varied in external populations (from 0·652 to 0·761). The new score outperformed other published risk scores in some, but not all, populations. An 8 (95 per cent c.i. 5 to 11) per cent improvement in the C‐statistic was estimated compared with using age alone. Conclusion The assessed risk scores did not have sufficient accuracy to enable potentially life‐saving decisions to be made regarding intervention. Focus should therefore shift to offering repair to more patients and reducing non‐intervention rates, while respecting the wishes of the patient and family.

1 August 2019 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
RIReza Indrakusuma
Reza Indrakusuma
LDLaura M. Drudi
Laura M. Drudi

1 August 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
HJHamid Jalalzadeh
Hamid Jalalzadeh
RIReza Indrakusuma
Reza Indrakusuma
JBJan D. Blankensteijn
Jan D. Blankensteijn
WWWillem Wisselink
Willem Wisselink
KYKak K Yeung
Kak K Yeung
RBRon Balm
Ron Balm
Introduction: The pathophysiology and natural course of abdominal aortic aneurysms (AAAs) are insufficiently understood. In order to improve our understanding, it is imperative to carry out longitudinal research that combines biomarkers with clinical and imaging data measured over multiple time points. Therefore, a multicentre biobank, databank and imagebank has been established in the Netherlands: the ‘Pearl Abdominal Aortic Aneurysm’ (AAA bank).Methods and analysis: The AAA bank is a prospective multicentre observational biobank, databank and imagebank of patients with an AAA. It is embedded within the framework of the Parelsnoer Institute, which facilitates uniform biobanking in all university medical centres (UMCs) in the Netherlands. The AAA bank has been initiated by the two UMCs of Amsterdam UMC and by Leiden University Medical Center. Participants will be followed during AAA follow-up. Clinical data are collected every patient contact. Three types of biomaterials are collected at baseline and during follow-up: blood (including DNA and RNA), urine and AAA tissue if open surgical repair is performed. Imaging data that are obtained as part of clinical care are stored in the imagebank. All data and biomaterials are processed and stored in a standardised manner. AAA growth will be based on multiple measurements and will be analysed with a repeated measures analysis. Potential associations between AAA growth and risk factors that are also measured on multiple time points can be assessed with multivariable mixed-effects models, while potential associations between AAA rupture and risk factors can be tested with a conditional dynamic prediction model with landmarking or with joint models in which linear mixed-effects models are combined with Cox regression.Ethics and dissemination: The AAA bank is approved by the Medical Ethics Board of the Amsterdam UMC (University of Amsterdam).Trial registration number: NCT03320408.